Together, the current study provides insights into the mechanisms underlying autophagy and HSC activation/reversion via ATG2A, and suggests a potential therapeutic benefit for mitigating liver fibrosis by targeting this protein. This evidence concerns the gene ATG2A and Hepatic fibrosis.